#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

Available vaccines offer protection against cervical, anal, oral, liver and stomach cancers.

New research shows that treating these viruses can reduce liver cancer risk.

Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.

A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.

Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.

Those with NAFLD or NASH and cirrhosis should undergo regular screening.

Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.

The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.

Smoking cessation, moderate drinking, a healthy diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer.

Successful treatment with direct-acting antivirals prolonged survival by 18 months.

People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

People with liver cirrhosis often have substantial financial burden that interferes with their care.